• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Knowledge PORTALS System (KPS)

Knowledge PORTALS System (KPS) @LPBI

Knowledge PORTALS System (KPS) @LPBI is an initiative launched in September 2020 to manage the content creation @LPBI by our Final Improvement Team (FIT) members during the Transition Period that started on March 14, 2020 with the Launch of the Coronavirus Portal to cover eight aspects of the SARS-CoV-2 Pandemic @LPBI and which will end when CDC will announce that this Pandemic is over.

KPS is an infrastructure initiative designed to facilitate valuation for the following Intellectual Property Asset Classes:

Asset Class
IV
Platforms

1.0 LPBI

 composition of methods and workflows for the content creation of scientific curations

 Valuation

~~~ $1.5MM

Platforms:

Five PORTALS & New Website

2.0 LPBI

$5MM
Asset Class
VI
Team of Experts: Human Capital component _____________

~$3MM

(1) BIOs Final Improvement Team (FIT)

(2) Activities till 3/14/2020

(3) Activities during the Transition Period

(4) Activities post Transition Period

1.0 & 2.0 LPBI Group’s Team

  • Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
  • Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
  • Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
  • Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications
  • Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases

INACTIVE 12/31/2021

  • Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery

INACTIVE 12/31/2022

  • Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications

INACTIVE 12/31/2022

  • Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

Joel Shertok, PhD – Affiliation with LPBI Group: 12/22/2019 – 5/4/2021

  • Joel Shertok, PhD, ex-Member of The Board, ex-Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

Justin D. Pearlman – External Scientific Relations: starting 5/12/2021

  • Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author

Revised_Org_chart_LPBI_v5

SCIENCE – Domains of Expertise

Responsibilities @LPBI:

(1) Curator initiated new content creation

(2) Updates to own published articles in the Journal

(3) Commissions by the Editor-in-Chief – One curation per WEEK

(4) Client facing engagement with External relations

(5) Advice for the Founder

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6

 https://pharmaceuticalintelligence.com/vision/

TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector –THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: Joint venture with Dr. Nir for Drug Discovery

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

  • Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences

Roles @ PharmaceuticalIntelligence.com

  • Scientific Counsel: Life Sciences
  • Advisor to the Founder
  • Dr. Stephen J. Williams – Cancer, Oncology Therapeutics & Genomics [Member of the Board]

(1)    TNS #1: https://www.wolfram.com/featureset/machine-learning/

1.1   LPBI LEAD on Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language

1.2   LPBI LEAD on Application on the ingress TEXT from: Cancer Volume 1 & 2 and Genomics Volume 1 & 2 

1.3   LPBI LEAD on Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

  • The Wolfram Solution for Biological Sciences
  • The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations

(2)    TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: Blockchain vendor – lined them up and are willing to build the Front End

(3)    Co-Editor LPBI Group’s BioMed Book #17 – COMPLETE Editorials by 12/10/2020

  • Justin D. Pearlman MD PhD – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author

TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS mean Knowledge VALUE 

  • Phase 1: Proof of Concept for 16 articles on Cardiovascular Diseases viewed >2,000
  • Phase 2: Scale up to SIX volumes on Cardiovascular Diseases

https://lnkd.in/e6WkMgF

  • Phase 3: Scale up to all articles in all CVD categories of Research
  • Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery

(1)    TNS #1: https://www.wolfram.com/featureset/machine-learning/

1.1   LPBI LEAD on Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language

1.2   LPBI LEAD on Application on the ingress TEXT from: Cancer Volume 1 & 2 and Genomics Volume 1 & 2 

1.3   LPBI LEAD on Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

  • The Wolfram Solution for Biological Sciences
  • The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations

(2)   Commissions by the Editor-in-Chief – One Curation per WEEK

(3)   TNS #5: Joint venture with Dr. Nir for Drug Discovery

  • Prof. Sudipta Saha – Reproductive Biology (Specifically sperm motility), Bio Instrumentation, Cell Biology (Specifically cell cycle regulation).

(1) Curator initiated new content creation

(2) Updates to own published articles in the Journal

(3) Commissions by the Editor-in-Chief – One Curation per WEEK

(4) Co-Editor LPBI Group’s BioMed Book #17 – COMPLETE Editorials by 12/10/2020

(5) When LPBI works on TNS #1: Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice: 

  • The Wolfram Solution for Biological Sciences

(5) Involvement with OWN created Content undergoing Text Analysis in TNS #1: Phase 3: Scaling up – Insights Interpretation stage

  • Aviva Lev-Ari, PhD, RN – Curation Methodology & Cardiovascular Diseases 

Founder & Director

  • 1.0 LPBI Group, 4/2012  – 12/2020
  • 2.0 LPBI Group, 1/2021 – 12/2025 

Roles on 1.0 LPBI Group’s: (1) Transfer of IP Ownership and (2) Teams Exit

  • Sourcing IB(s) and or Acquirer(s)
  • Shepard Exit Transaction completion
  • Transition under new ownership of LPBI IP portfolio

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 

Author: 2020 VISION

  • 2.0 LPBI Group, 1/2021 – 12/2025 

https://pharmaceuticalintelligence.com/vision/

TNS #1: SEE https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector –THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA – Provide input in the selection of Interviewees

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: Joint venture with Dr. Nir for Drug Discovery

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

BUSINESS & SCIENCE – Domains of Expertise

  • Ofer Markman, PhD

Science: AI in healthcare, AI in medical diagnosis, BioIT Bioinformatics, Biomarkers and medical diagnostics, Glycobiology, Cancer and current Therapeutics, Microbiome, Clinical diagnostics, Diagnostic immunology

Business:

  1. Biotech venture creation
  2. Joint Venture 2.0 LPBI Group (30%) with ABI-Lab (70%)

Business Development responsibilities @LPBI: Biotech in Israel, in Switzerland and in other countries in Europe

Plan for Business Development Activity at 1.0 LPBI 4Q 2020

  • TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

    Phase 1: Natural Language Processing(NLP) – 12 months FREE Microsoft AZURE for Health

    • Text Analysis done in parallel on three LPBI’s Article Collections building a Proof of Concept performed byLPBI Group’s 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP): 9/2020 – 9/2021 – Academic INTERNSHIPS in LIFE SCIENCES, Medicine, Biological Sciences, Drug Discovery 
    • Inputs for Proof of Concept are the following three:

    (1) Top 12 articles by views (all domains)

    (2) Sixteen Cancer Articles representing 8 topics in Cancer Volume 1

    (3) Sixteen Genomics Articles representing 21 chapters in Genomics Volume 1

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

TNS #1: See above

TNS #2: EXEMPT due to conflict of interests

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: Joint venture with Dr. Nir for Drug Discovery

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Plan for Business Development Activity at 2.0 LPBI 1Q 2021

  • PENDING
  • Gail S. Thornton, MA, PhD(c)

Science: Primary qualitative data collection: Interviewing techniques for content creation: e-Voices of Patients and Podcasts with scientific leaders, Customer Surveys design and collateral marketing communication content production

Business: Global communications consultant in pharmaceuticals/health care and biotechnology

Business Development responsibilities @LPBI: Monthly Newsletter and e-Voices Podcasts, emergence of an Audio & Video Library

2020 RESULTS

Plan for Business Development Activity at 1.0 LPBI 4Q 2020

  • One newsletter, two podcasts, collaboration on web site design, regular article posting on LPBI web site

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

TNS #1: Not Applicable

TNS #2: Development of LPBI’s Narrowcasting messages for Blockchain Partner’s clients

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA – See 2020-2021 RESULTS

  • Development Plan for e-VOICES Podcasting, 2019 – 2021*

    https://pharmaceuticalintelligence.com/audio-podcasts/

    Podcast Interviewer INTERVIEWEE(S) Subject Date Audio/Video/

    Narrator

    Gail S. Thornton Dr. Stephen J. Williams, Dr. Irina Robu & Dr. Aviva Lev-Ari 3D BioPrinting in Medicine 5/2019 Audio
    Gail S. Thornton Prof. Feldman Evolution Biology and Population Genetics 3/17/2020 Audio
    Gail S. Thornton Dr. Larry H. Bernstein, MD, FCAP Life Memoirs in Clinical Pathology Told 8/2020 Audio

    Narrator: Dr. S.J. Williams

    Gail S. Thornton Dr. Justin D. Pearlman, MD, PhD Cardiac Imaging – Evolution of Diagnostic Methods 4Q 2020 Audio
    Gail S. Thornton Dr. Raphael Nir From Big Pharma to Biotech Entrepreneurship 2021 Audio
    Gail S. Thornton Dr. Meg Baker GlycoBiology in Practice 2021 Audio
    Gail S. Thornton Dr. Ofer Markman Memories of

    Procognia

    2021 Audio

    *Dr. Williams and Aviva – will have their Podcasts in 2021.

TNS #4: Conversion – Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: Not Applicable

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Plan for Business Development Activity at 2.0 LPBI 1Q 2021

  • One newsletter, two podcasts, continued refinement of web site design, regular article posting on LPBI web site

BUSINESS – Domains of Expertise

  • Joel T. Shertok, PhD [Board Member]

Verticals: (1) Chemical Industry (2) Financials & Insurance: Health Care (3) Biotech (4) Private Equity

Business Development responsibilities @LPBI:

(1) All Documentation Artifacts expected by External Relations

(2) Client facing engagement with External relations: Information Syndication

(3) Development of a Bot-based Global Prospecting System for LPBI

3.1 applications on ALA’s 7,200

3.2 applications on JTS’s 1st degree connections on LinkedIn

(4) LPBI’s LEAD all efforts with IB

(5) LPBI’s LEAD for all Partnerships:

5.1 LPBI J-V (30%) with ABI-Lab (70%)

5.2 Blockchain vendor

5.3 Agreements with Wolfram Machine Learning Approach https://www.wolfram.com/featureset/machine-learning/ 

Plan for Business Development Activity at 1.0 LPBI 4Q 2020

  • 1,4,5, ABOVE

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

  • 2,3,5, ABOVE

TNS #1: See 5.3, above – TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

TNS #2: See 5.2, above, Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: See 5.1, above Joint venture with Dr. Nir for Drug Discovery: 

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Plan for Business Development Activity at 2.0 LPBI 1Q 2021

  • See 5.1, 5.2, 5.3, above

PROCESS of EMBEDDING A VIDEO on A PAGE on our Knowledge PORTALS System 

[same for ANY PAGE on the website]

  1. You click on the VIDEO link 
  2. You select a video you wish to embed
  3. You click on share – click on option <<EMBED>>> copy the link provided for embedding
  4. You go to our DASHBOARD
  5. You click all pages
  6. You type in name of the PAGE you manage on the Portal
  7. You find the Page and click EDIT
  8. You type the date
  9. You PASTE the embed link and the URL on Youtube
  10. You UPDATE 
  11. You go to View Page
  12. You WATCH the VIDEO on our website

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

This page has the following sub pages.

  • Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
  • Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
  • Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
  • Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
  • Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
  • Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases and Co-Editor, Series D, Volume 4: Human Reproduction System
  • Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
  • Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
  • Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 9,459 other subscribers
  • Recent Posts

    • Creating a Twitter Space for @pharma_BI for Live Broadcasts March 14, 2023
    • The Vibrant Philly Biotech Scene: Recent Happenings & Deals March 11, 2023
    • Peak oxygen uptake (VO2peak) quantified fitness: Lifelong and late-onset athletes had higher VO2peak than non-athletes March 7, 2023
    • Merck’s sotatercept overachieves, PCSK9 inhibitor passes phase 2 March 6, 2023
    • Bacterial multidrug resistance problem solved by a broad-spectrum synthetic antibiotic March 1, 2023
    • Genetic variation causes human lupus, systemic lupus erythematosus (SLE) February 23, 2023
    • Mimicking vaginal cells and microbiome interactions on chip microfluidic culture February 14, 2023
    • Press Release for Five Bilingual BioMed e-Series in English and in Spanish January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    %d bloggers like this: